ArticleFrontiers in oncology2021
Plasma-Derived Exosomal ALIX as a Novel Biomarker for Diagnosis and Classification of Pancreatic Cancer.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Extracellular vesicle biomarkers for pancreatic cancer diagnosis: a systematic review and meta-analysis.BMC cancer · 2022Pooled it
- Extracellular vesicle biomarkers in pancreatic ductal adenocarcinoma: from bulk detection to single-extracellular vesicle profiling and endoscopic liquid biopsy.Journal of gastroenterology · 2026Review
- Diagnostic and prognostic significance of circulating extracellular vesicles in gastrointestinal cancers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Extracellular Vesicles in Pancreatic Cancer Function and Potential Clinical Applications.OncoTargets and therapy · 2026Review
- Exosomal Protein Markers as Potential Non-Invasive Biomarkers for Colorectal Cancer.International journal of molecular sciences · 2025Article
- Exosomes in Clinical Laboratory: From Biomarker Discovery to Diagnostic Implementation.Medicina (Kaunas, Lithuania) · 2025Review
- Diagnostic methods for pancreatic cancer and their clinical applications (Review).Oncology letters · 2025Review
- Proteomic profiles screening identified novel exosomal protein biomarkers for diagnosis of lung cancer.Clinical proteomics · 2025Article
- Secretory exosomes from modified immune cells against cancer.Medical oncology (Northwood, London, England) · 2025Review
- Small extracellular vesicles (sEVs) in pancreatic cancer progression and diagnosis.Journal of controlled release : official journal of the Controlled Release Society · 2025Review
- Extracellular matrix ligands modulate the endothelial progenitor cell secretome for enhanced angiogenesis.Acta biomaterialia · 2025Article
- Prospect of extracellular vesicles in tumor immunotherapy.Frontiers in immunology · 2025Review
- Diagnostic and Prognostic Significance of Exosomes and Their Components in Patients With Cancers.Cancer medicine · 2025Review
- Current trends in theranostic applications of extracellular vesicles in cancer.Frontiers in oncology · 2025Review
- Neuroendocrine gene subsets are uniquely dysregulated in prostate adenocarcinoma.Cancer biology & therapy · 2024Article
- Comparison of nanoimaging and nanoflow based detection of extracellular vesicles at a single particle resolution.Journal of extracellular biology · 2024Article
- Review
- Article
- The systematic role of pancreatic cancer exosomes: distant communication, liquid biopsy and future therapy.Cancer cell international · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic cancer (PC) has a dismal prognosis due to its insidious early symptoms and poor early detection rate. Exosomes can be released by various cell types and tend to be a potential novel biomarker for PC detection. In this study, we explored the proteomic profiles of plasma exosomes collected from patients with PC at different stages and other pancreatic diseases.
methodsPlasma samples were collected from six groups of patients, including PC at stage I/II, PC at stage III/IV, well-differentiated pancreatic neuroendocrine tumor (P-NET), pancreatic cystic lesions (PCLs), chronic pancreatitis (CP), and healthy controls (HCs). Plasma-derived exosomes were isolated by ultracentrifugation and identified routinely. Isobaric tags for relative and absolute quantification (iTRAQ) based proteomic analysis along with bioinformatic analysis were performed to elucidate the biological functions of proteins. The expression of exosomal ALIX was further confirmed by enzyme-linked immunosorbent assay in a larger cohort of patients. Furthermore, receiver operating characteristic curve analysis was applied to evaluate the potential of ALIX as a novel diagnostic biomarker.
resultsThe proteomic profile revealed a total of 623 proteins expressed among the six groups, and 16 proteins with differential degrees of abundance were found in PC
conclusionIn summary, our study demonstrated that based on proteomic profiling, proteins isolated from the plasma-derived exosomes may function as ideal non-invasive biomarkers for the clinical diagnosis of PC. Importantly, exosomal ALIX combined with CA199 has great potentials in detection of PC, especially in distinguishing PC patients at early stages from advanced stages.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.